Medeor Therapeutics Overview
- Founded
- 2012
- Status
- Private
- Latest Deal Type
- Debt - PPP
- Investors
- 6
Medeor Therapeutics General Information
Description
Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.
Contact Information
Website
Formerly Known As
SERC Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Medeor Therapeutics Timeline
Medeor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Debt - PPP | 29-Apr-2020 | 000.00 | Completed | |||
| 5. Grant | 22-Jan-2018 | 000.00 | 000.00 | Completed | Clinical Trials - General | |
| 4. Early Stage VC (Series B) | 27-Nov-2017 | 0000 | 000.00 | 00000 | Completed | Clinical Trials - General |
| 3. Early Stage VC (Series A) | 16-Oct-2015 | 000 | 000.00 | 0000 | Completed | Clinical Trials - General |
| 2. Early Stage VC | 02-Oct-2013 | $1.55M | $2.55M | 000.00 | Completed | Clinical Trials - General |
| 1. Seed Round | 11-Jan-2013 | $1M | $1M | 000 | Completed | Clinical Trials - General |
Medeor Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series A | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Seed 1 | 1,291,667 | $0.000100 | 8% | $1.2 | $1.2 | 1x | $1.2 | 4.67% |
| Seed | 1,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 3.61% |
Medeor Therapeutics Executive Team (12)
Medeor Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anand Mehra MD | Sofinnova Investments | Board Member | 000 0000 |
| Chih-Ping Liu Ph.D | Self | Co-Founder and Chairman | 000 0000 |
| Frank Kung Ph.D | Vivo Capital | Board Member | 000 0000 |
| Peter Kolchinsky Ph.D | RA Capital Management | Board Observer | 000 0000 |
| Wei Li Ph.D | WuXi Healthcare Ventures | Board Member | 000 0000 |
Medeor Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine | Government | 000 0000 | 000000 0 | ||
| 6 Dimensions Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| RA Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Sofinnova Investments | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Vivo Capital | Venture Capital | Minority | 000 0000 | 000000 0 |